ICON Plc shares plummeted in premarket trading after the health care services contractor disclosed a potential overstatement of past revenue and withdrew its annual guidance. The Dublin-based company, which provides clinical research services to pharmaceutical and biotech firms, said it is launching an accounting probe to investigate the discrepancies. ICON Plc shares fell sharply, reflecting investor concern over the financial implications of the restatement and the uncertainty surrounding the company's future performance.

The revenue overstatement raises questions about ICON's internal controls and financial reporting practices. The company's decision to pull its guidance suggests the accounting issues could be significant enough to impact its projected earnings and revenue for the year. This development comes at a time when ICON has been expanding its services and acquiring smaller firms to strengthen its position in the competitive clinical research market. The accounting probe may delay or complicate these strategic initiatives.

Investors reacted swiftly to the news, with ICON's stock price dropping as much as 15% in premarket trading. The company's market value took a substantial hit, erasing millions in shareholder wealth. ICON has not provided a timeline for completing the accounting investigation or for reinstating its financial guidance. The market will be closely watching for updates on the probe's findings and any potential restatements of past financial statements.